Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody therapeutics, and ABL Bio Inc. ("ABL", KOSDAQ: 298380), a Korean biotechnology company with clinical development products that develops novel therapeutics in oncology and for the treatment of CNS diseases, today announced their cooperation to develop new bispecific antibody-active ingredient conjugates (bsADCs).

The RenLite^® mouse platform from Biocytogen can produce completely human antibodies with different epitopes and high affinity. This platform is characterized by its ability to generate antibodies in a common light chain format by offering an unmistakable combination of design flexibility, simplified manufacturing processes and optimal developability for the development of bsADCs. Based on this platform, both companies will be able to discuss the expansion of their collaboration for different types of development of antibody-active ingredient conjugates.

Dr. Yuelei Shen, President and CEO of Biocytogen, said: "We are extremely pleased to work with ABL, a company that has advanced platforms for cancer immunotherapy and the treatment of CNS diseases. ABL's continued success in further developing its pipeline strongly demonstrates its expertise and capabilities in regulatory and clinical development as well as in business development activities. BsADC drugs derived from our RenLite ^® mouse platform were able to prove their better potency in different tumor models, while also having good safety profiles. We are convinced that our fully humane bsADC platform technology, which provides improved tumor selectivity, target-synergized internalization and convenient CMC development, will effectively complement the capabilities of ABL. Our common goal is to advance the development of innovative bsADC therapies."

Sang Hoon Lee, CEO of ABL, explained: "We are extremely pleased to be able to build this partnership with Biocytogen for bsADCs. This cooperation provides a good basis for the development of bsADCs. We look forward to a productive cooperation and are firmly convinced that this partnership will contribute to the creation of a distinctive pipeline that improves the quality of life of patients."